董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary S. Guthart | 男 | Director | 49 | 15.87万美元 | 未持股 | 2015-03-31 |
| Jami Dover Nachtsheim | 女 | Director | 56 | 18.17万美元 | 未持股 | 2015-03-31 |
| Robert H. Trice | 男 | Director | 68 | 16.96万美元 | 未持股 | 2015-03-31 |
| Merilee Raines | 女 | Director | 58 | 未披露 | 未持股 | 2015-03-31 |
| Nelson C. Chan | 男 | Director | 53 | 18.86万美元 | 未持股 | 2015-03-31 |
| Frank Witney | 男 | President and Chief Executive Officer & Director | 61 | 219.86万美元 | 未持股 | 2015-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew J. Last | 女 | Executive Vice President and Chief Operating Officer | 55 | 123.64万美元 | 未持股 | 2015-03-31 |
| Andrew J. Last | 男 | Executive Vice President and Chief Operating Officer | 55 | 未披露 | 未持股 | 2015-03-31 |
| Frank Witney | 男 | President and Chief Executive Officer & Director | 61 | 219.86万美元 | 未持股 | 2015-03-31 |
| David Weber | 男 | Executive Vice President and Chief Commercial Officer | 61 | 119.97万美元 | 未持股 | 2015-03-31 |
| Gavin Wood | 男 | Executive Vice President and Chief Financial Officer | 45 | 115.86万美元 | 未持股 | 2015-03-31 |
董事简历
中英对照 | 中文 | 英文- Gary S. Guthart
-
Gary S. Guthart，他于1996年4月加入了Intuitive Surgical，2010年1月，Guthart博士被任命为首席执行官。2007年7月，他被提升为董事长。在此之前，2006年2月，Guthart博士担任首席运营官。加入Intuitive Surgical之前，Guthart博士是SRI国际斯坦福研究所核心团队的一员负责开发计算机提高外科手术技术。自2009年5月，Guthart博士担任美国昂飞公司董事会的一员，他获得了加利大学伯克利分校的工程学士学位和加州理工学院工程硕士和博士学位。
Gary S. Guthart,has been director since December 2017. Dr. Guthart is currently President and Chief Executive Officer of Intuitive Surgical, a global leader in the field of robotic-assisted minimally invasive surgery. He joined Intuitive Surgical in April 1996 and has served as the Chief Executive Officer since January 2010. In July 2007, he was promoted to President, having assumed the role of Chief Operating Officer in February 2006. Prior to joining Intuitive Surgical, Dr. Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formerly Stanford Research Institute). Dr. Guthart served as a member of the Board of Directors of Affymetrix, Inc. from May 2009 until its acquisition by Thermo Fisher Scientific Inc. in March 2016.Dr. Guthart received a B.S. in Engineering from the University of California, Berkeley and an M.S. and a Ph.D. in Engineering Science from the California Institute of Technology. - Gary S. Guthart，他于1996年4月加入了Intuitive Surgical，2010年1月，Guthart博士被任命为首席执行官。2007年7月，他被提升为董事长。在此之前，2006年2月，Guthart博士担任首席运营官。加入Intuitive Surgical之前，Guthart博士是SRI国际斯坦福研究所核心团队的一员负责开发计算机提高外科手术技术。自2009年5月，Guthart博士担任美国昂飞公司董事会的一员，他获得了加利大学伯克利分校的工程学士学位和加州理工学院工程硕士和博士学位。
- Gary S. Guthart,has been director since December 2017. Dr. Guthart is currently President and Chief Executive Officer of Intuitive Surgical, a global leader in the field of robotic-assisted minimally invasive surgery. He joined Intuitive Surgical in April 1996 and has served as the Chief Executive Officer since January 2010. In July 2007, he was promoted to President, having assumed the role of Chief Operating Officer in February 2006. Prior to joining Intuitive Surgical, Dr. Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formerly Stanford Research Institute). Dr. Guthart served as a member of the Board of Directors of Affymetrix, Inc. from May 2009 until its acquisition by Thermo Fisher Scientific Inc. in March 2016.Dr. Guthart received a B.S. in Engineering from the University of California, Berkeley and an M.S. and a Ph.D. in Engineering Science from the California Institute of Technology.
- Jami Dover Nachtsheim
-
Jami Dover Nachtsheim，自2017年4月起成为直觉外科公司董事会成员。Nachtsheim女士从1980年到2000年退休，曾在半导体公司英特尔公司担任过多个职位，最近担任销售和营销集团的公司副总裁兼全球营销总监。Nachtsheim女士从2012年2月开始担任FEI公司的董事会成员。Nachtsheim女士还于2010年3月在生命科学公司Affymetrix, Inc.的董事会任职，并于2015年1月开始担任董事长。Nachtsheim女士自2019年3月起担任生物医药产品公司Cerus Corp.的董事会成员，自2021年6月起担任生物公司Telesis Bio Inc.的董事会成员。Nachtsheim女士拥有亚利桑那州立大学商业管理学士学位。
Jami Dover Nachtsheim,has been a member of Intuitive Surgical, Inc. Board since April 2017. Ms. Nachtsheim served in a variety of positions with Intel Corporation, a semiconductor company, from 1980 until her retirement in 2000, most recently as the Corporate Vice President of the Sales and Marketing Group and Director of Worldwide Marketing. Ms. Nachtsheim served on the Board of Directors of FEI Company, a high-performance electron microscopy company, from February 2012 until its acquisition by Thermo Fisher Scientific Inc. in September 2016. Ms. Nachtsheim also served on the Board of Directors of Affymetrix, Inc., a life sciences company, from March 2010, and as Chairman starting January 2015, until its acquisition by Thermo Fisher Scientific Inc. in March 2016. Ms. Nachtsheim has served on the Board of Directors of Cerus Corp., a biomedical products company, since March 2019 and Telesis Bio Inc., a biology company, since June 2021. Ms. Nachtsheim has served as a member of the Board of Directors of several other public and private companies. Ms. Nachtsheim holds a B.S. in Business Management from Arizona State University. - Jami Dover Nachtsheim，自2017年4月起成为直觉外科公司董事会成员。Nachtsheim女士从1980年到2000年退休，曾在半导体公司英特尔公司担任过多个职位，最近担任销售和营销集团的公司副总裁兼全球营销总监。Nachtsheim女士从2012年2月开始担任FEI公司的董事会成员。Nachtsheim女士还于2010年3月在生命科学公司Affymetrix, Inc.的董事会任职，并于2015年1月开始担任董事长。Nachtsheim女士自2019年3月起担任生物医药产品公司Cerus Corp.的董事会成员，自2021年6月起担任生物公司Telesis Bio Inc.的董事会成员。Nachtsheim女士拥有亚利桑那州立大学商业管理学士学位。
- Jami Dover Nachtsheim,has been a member of Intuitive Surgical, Inc. Board since April 2017. Ms. Nachtsheim served in a variety of positions with Intel Corporation, a semiconductor company, from 1980 until her retirement in 2000, most recently as the Corporate Vice President of the Sales and Marketing Group and Director of Worldwide Marketing. Ms. Nachtsheim served on the Board of Directors of FEI Company, a high-performance electron microscopy company, from February 2012 until its acquisition by Thermo Fisher Scientific Inc. in September 2016. Ms. Nachtsheim also served on the Board of Directors of Affymetrix, Inc., a life sciences company, from March 2010, and as Chairman starting January 2015, until its acquisition by Thermo Fisher Scientific Inc. in March 2016. Ms. Nachtsheim has served on the Board of Directors of Cerus Corp., a biomedical products company, since March 2019 and Telesis Bio Inc., a biology company, since June 2021. Ms. Nachtsheim has served as a member of the Board of Directors of several other public and private companies. Ms. Nachtsheim holds a B.S. in Business Management from Arizona State University.
- Robert H. Trice
-
Robert H. Trice，博士，自2006年起一直担任董事，他是提名和公司治理委员会的主席和审计委员会的成员。从1998年10月起，他担任洛克希德·马丁公司业务发展部门的高级副总裁，从2009年3月到2011年1月退休，他担任洛克希德·马丁公司战略和业务发展部门的高级副总裁。
Robert H. Trice, Ph.D., has served as a director since 2006 is the Chairman of the Nominating and Corporate Governance Committee and a member of the Audit Committee. Dr. Trice served as Senior Vice President for Business Development at Lockheed Martin Corporation from October 1998 and assumed additional duties as Senior Vice President for Strategy and Business Development at Lockheed Martin Corporation from March 2009 until his retirement in January 2011. The Board of Directors selected Dr. Trice as a director nominee because of his broad experience in government relationships many of our large customers are government institutions and his extensive background as a business development leader. - Robert H. Trice，博士，自2006年起一直担任董事，他是提名和公司治理委员会的主席和审计委员会的成员。从1998年10月起，他担任洛克希德·马丁公司业务发展部门的高级副总裁，从2009年3月到2011年1月退休，他担任洛克希德·马丁公司战略和业务发展部门的高级副总裁。
- Robert H. Trice, Ph.D., has served as a director since 2006 is the Chairman of the Nominating and Corporate Governance Committee and a member of the Audit Committee. Dr. Trice served as Senior Vice President for Business Development at Lockheed Martin Corporation from October 1998 and assumed additional duties as Senior Vice President for Strategy and Business Development at Lockheed Martin Corporation from March 2009 until his retirement in January 2011. The Board of Directors selected Dr. Trice as a director nominee because of his broad experience in government relationships many of our large customers are government institutions and his extensive background as a business development leader.
- Merilee Raines
-
Merilee Raines ，一直担任Watts Water Technologies, Inc.的董事会成员。Raines女士被任命为TransMedics Group公司的董事会成员，TransMedics Group公司是一家从事器官移植治疗的医疗技术公司，自2021年1月1日起生效。她还担任审计委员会成员，并将成为主席，自2021年6月1日起生效。Raines女士还曾在Aranta Therapeutics，Inc.的董事会任职，Aranta Therapeutics，Inc.是一家生物制药公司，专注于宠物伴侣市场的许可、开发和商业化产品。Raines女士目前是Excelitas Technologies Corporation的董事会成员，Excelitas Technologies Corporation是一家私营的全球工业技术公司，提供传感和检测解决方案，并担任其审计委员会主席。Raines女士是Dead River Company的董事会成员，Dead River Company是一家私营能源产品分销商，并在其财务和风险管理委员会任职。Raines女士此前曾是Affymetrix, Inc.的董事会成员，Affymetrix, Inc.是一家生命科学产品和分子诊断产品的上市供应商，在2015年1月至2016年4月期间，赛默飞世尔科学公司收购了Affymetrix。Raines女士此前还曾在PetVet Care Centers LLC的董事会任职。Raines女士于2003年10月至2013年5月退休期间，曾担任爱德士，Inc.的首席财务官，主要向伴侣动物健康市场提供诊断和IT产品及服务。Raines女士是注册会计师非活跃状态。1977年，她获得了鲍登学院的数学学士学位。1979年，她获得了芝加哥大学的硕士学位。
Merilee Raines has been a member of the Company's Board of Directors since 2018 and is a member of the Board's Audit Committee. Since 2011 Ms. Raines has been a member of the Board of Directors of Watts Water Technologies, Inc., a publicly traded manufacturer of products and systems focused on control, conservation and quality of water. She is currently a member of that company's Nominating and Corporate Governance Committee, and she serves as Chair of its Audit Committee. Ms. Raines was appointed to the Board of Directors of TransMedics Group, Inc., a medical technology company involved in organ transplant therapy, effective January 1 2021. She also serves as a member of the Audit Committee and will become the Chair effective June 1 2021. Ms. Raines also served on the Board of Directors of Aranta Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing products for the pet companion market, from 2014 until the company was acquired by Elanco Animal Health Incorporated in July 2019. Ms. Raines is currently a member of the Board of Directors of Excelitas Technologies Corporation, a privately held global industrial technology company providing sensing and detection solutions, and is Chair of its Audit committee. Ms. Raines is a member of the Board of Directors of Dead River Company, a privately held distributor of energy products and serves on its Finance and Risk Management committees. Ms. Raines was previously a member of the Board of Directors of Affymetrix, Inc., a publicly traded provider of life sciences products and molecular diagnostic products, from January 2015 to April 2016 when Thermo Fisher Scientific, Inc. acquired Affymetrix. Ms. Raines also previously served on the board of PetVet Care Centers LLC, a privately owned operator of a network of veterinary hospitals from April 2016 to February 2018 when KKR acquired PetVet. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly traded company providing diagnostic and IT products and services primarily to the companion animal health market, from October 2003 until her retirement in May 2013. Ms. Raines is a Certified Public Accountant inactive status. She received a Bachelor's Degree in Mathematics from Bowdoin College, in 1977. In 1979 she received her MBA from the University of Chicago. - Merilee Raines ，一直担任Watts Water Technologies, Inc.的董事会成员。Raines女士被任命为TransMedics Group公司的董事会成员，TransMedics Group公司是一家从事器官移植治疗的医疗技术公司，自2021年1月1日起生效。她还担任审计委员会成员，并将成为主席，自2021年6月1日起生效。Raines女士还曾在Aranta Therapeutics，Inc.的董事会任职，Aranta Therapeutics，Inc.是一家生物制药公司，专注于宠物伴侣市场的许可、开发和商业化产品。Raines女士目前是Excelitas Technologies Corporation的董事会成员，Excelitas Technologies Corporation是一家私营的全球工业技术公司，提供传感和检测解决方案，并担任其审计委员会主席。Raines女士是Dead River Company的董事会成员，Dead River Company是一家私营能源产品分销商，并在其财务和风险管理委员会任职。Raines女士此前曾是Affymetrix, Inc.的董事会成员，Affymetrix, Inc.是一家生命科学产品和分子诊断产品的上市供应商，在2015年1月至2016年4月期间，赛默飞世尔科学公司收购了Affymetrix。Raines女士此前还曾在PetVet Care Centers LLC的董事会任职。Raines女士于2003年10月至2013年5月退休期间，曾担任爱德士，Inc.的首席财务官，主要向伴侣动物健康市场提供诊断和IT产品及服务。Raines女士是注册会计师非活跃状态。1977年，她获得了鲍登学院的数学学士学位。1979年，她获得了芝加哥大学的硕士学位。
- Merilee Raines has been a member of the Company's Board of Directors since 2018 and is a member of the Board's Audit Committee. Since 2011 Ms. Raines has been a member of the Board of Directors of Watts Water Technologies, Inc., a publicly traded manufacturer of products and systems focused on control, conservation and quality of water. She is currently a member of that company's Nominating and Corporate Governance Committee, and she serves as Chair of its Audit Committee. Ms. Raines was appointed to the Board of Directors of TransMedics Group, Inc., a medical technology company involved in organ transplant therapy, effective January 1 2021. She also serves as a member of the Audit Committee and will become the Chair effective June 1 2021. Ms. Raines also served on the Board of Directors of Aranta Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing products for the pet companion market, from 2014 until the company was acquired by Elanco Animal Health Incorporated in July 2019. Ms. Raines is currently a member of the Board of Directors of Excelitas Technologies Corporation, a privately held global industrial technology company providing sensing and detection solutions, and is Chair of its Audit committee. Ms. Raines is a member of the Board of Directors of Dead River Company, a privately held distributor of energy products and serves on its Finance and Risk Management committees. Ms. Raines was previously a member of the Board of Directors of Affymetrix, Inc., a publicly traded provider of life sciences products and molecular diagnostic products, from January 2015 to April 2016 when Thermo Fisher Scientific, Inc. acquired Affymetrix. Ms. Raines also previously served on the board of PetVet Care Centers LLC, a privately owned operator of a network of veterinary hospitals from April 2016 to February 2018 when KKR acquired PetVet. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly traded company providing diagnostic and IT products and services primarily to the companion animal health market, from October 2003 until her retirement in May 2013. Ms. Raines is a Certified Public Accountant inactive status. She received a Bachelor's Degree in Mathematics from Bowdoin College, in 1977. In 1979 she received her MBA from the University of Chicago.
- Nelson C. Chan
-
Nelson C. Chan，自2018年10月起担任Synaptics Incorporated（“Synaptics”）董事会主席，自2007年2月起担任Synaptics董事。从2006年12月到2008年8月，他担任Magellan Corporation的首席执行官，Magellan Corporation是消费者、调查、GIS和OEM GPS导航和定位市场的领导者。从1992年到2006年，他曾担任SanDisk Corporation（闪存卡的全球领导者）的各种高级管理职位，包括执行副总裁兼消费者业务总经理。1983年至1992年，他在Chips and Technologies、sigtics和Delco Electronics担任营销和工程职位。他是Deckers Outdoor Corporation（纽约证券交易所上市公司，鞋类、服装和配饰设计师和分销商）的董事会成员、审计委员会成员、提名和治理委员会成员，也是Twist Bioscience（纳斯达克上市公司，制造合成DNA）的董事会成员、审计委员会成员、提名和治理委员会成员。他目前还担任几家私人公司的董事会成员。此前，他曾担任纳斯达克上市公司Adesto Technologies的董事会主席、薪酬委员会主席、审计委员会成员和提名和公司治理委员会成员（2010年至2020年6月，在被Dialog Semiconductor plc收购之前），以及纳斯达克上市公司Socket Mobile的董事会成员、薪酬委员会主席和提名和公司治理委员会成员。从2016年到2019年，他是纳斯达克上市公司Silicon Laboratories， Inc.的董事会成员，从2007年到2010年，他是Affymetrix的董事会成员，审计委员会主席和薪酬委员会成员，从2010年到2016年，在被Thermo Fisher收购之前，他是纳斯达克上市公司Outerwall的董事会成员和董事会主席，从2013年6月到2016年9月。在被Apollo Global Management（一家私募股权公司）收购之前。他持有California大学圣巴巴拉分校电气和计算机工程学士学位，以及Santa Clara大学工商管理硕士学位。
Nelson C. Chan From December 2006 until Augt 2008, Mr. Chan served as the Chief Executive Officer of Magellan Corporation, a leader in the consumer, survey, GIS, and OEM GPS navigation and positioning markets. From 1992 through 2006, Mr. Chan served in vario senior management positions with SanDisk Corporation, a global leader in flash memory cards, including as Executive Vice President and General Manager, Consumer Biness. From 1983 to 1992, Mr. Chan held marketing and engineering positions at Chips and Technologies, Signetics, and Delco Electronics.He currently serves on the board, audit committee, and nominating and governance committee of Deckers Outdoor Corporation (NYSE), a footar, apparel and accessories designer and distributor; on the board, audit committee, and nominating and governance committee of Twist Bioscience (NASDAQ), which manufactures synthetic DNA; and on the board and nominating and corporate governance committee of GCT Semiconductors (NYSE), a fabless designer and supplier of advanced 4G LTE, IoT and 5G semiconductor solutions. Mr. Chan also currently serves on the Boards of Directors of several private companies.Previoly, Mr. Chan was Chair of the board of directors, chair of the compensation committee, member of the audit committee and member of the nominating and corporate governance committee of Adesto Technologies (NASDAQ), from 2010 to June 2020, prior to its acquisition by Dialog Semiconductor plc. He also served on the board, as chair of the compensation committee, and on the nominating and corporate governance committee of Socket Mobile (NASDAQ), from 2016 to 2019. From 2007 to 2010, he was a member of the board of directors of Silicon Laboratories, Inc.(NASDAQ), and from 2010 to 2016, he was a member of the board and compensation committee, and chair of the audit committee, of Affymetrix, prior to its acquisition by Thermo Fisher. From June 2013 through September 2016, Mr. Chan also was chair of the board of Outerwall (NASDAQ) prior to its acquisition by Apollo Global Management, a private equity firm. Mr. Chan holds a Bachelor of Science degree in Electrical and Computer Engineering from the University of California at Santa Barbara and a Master's degree in Biness Administration from Santa Clara University. - Nelson C. Chan，自2018年10月起担任Synaptics Incorporated（“Synaptics”）董事会主席，自2007年2月起担任Synaptics董事。从2006年12月到2008年8月，他担任Magellan Corporation的首席执行官，Magellan Corporation是消费者、调查、GIS和OEM GPS导航和定位市场的领导者。从1992年到2006年，他曾担任SanDisk Corporation（闪存卡的全球领导者）的各种高级管理职位，包括执行副总裁兼消费者业务总经理。1983年至1992年，他在Chips and Technologies、sigtics和Delco Electronics担任营销和工程职位。他是Deckers Outdoor Corporation（纽约证券交易所上市公司，鞋类、服装和配饰设计师和分销商）的董事会成员、审计委员会成员、提名和治理委员会成员，也是Twist Bioscience（纳斯达克上市公司，制造合成DNA）的董事会成员、审计委员会成员、提名和治理委员会成员。他目前还担任几家私人公司的董事会成员。此前，他曾担任纳斯达克上市公司Adesto Technologies的董事会主席、薪酬委员会主席、审计委员会成员和提名和公司治理委员会成员（2010年至2020年6月，在被Dialog Semiconductor plc收购之前），以及纳斯达克上市公司Socket Mobile的董事会成员、薪酬委员会主席和提名和公司治理委员会成员。从2016年到2019年，他是纳斯达克上市公司Silicon Laboratories， Inc.的董事会成员，从2007年到2010年，他是Affymetrix的董事会成员，审计委员会主席和薪酬委员会成员，从2010年到2016年，在被Thermo Fisher收购之前，他是纳斯达克上市公司Outerwall的董事会成员和董事会主席，从2013年6月到2016年9月。在被Apollo Global Management（一家私募股权公司）收购之前。他持有California大学圣巴巴拉分校电气和计算机工程学士学位，以及Santa Clara大学工商管理硕士学位。
- Nelson C. Chan From December 2006 until Augt 2008, Mr. Chan served as the Chief Executive Officer of Magellan Corporation, a leader in the consumer, survey, GIS, and OEM GPS navigation and positioning markets. From 1992 through 2006, Mr. Chan served in vario senior management positions with SanDisk Corporation, a global leader in flash memory cards, including as Executive Vice President and General Manager, Consumer Biness. From 1983 to 1992, Mr. Chan held marketing and engineering positions at Chips and Technologies, Signetics, and Delco Electronics.He currently serves on the board, audit committee, and nominating and governance committee of Deckers Outdoor Corporation (NYSE), a footar, apparel and accessories designer and distributor; on the board, audit committee, and nominating and governance committee of Twist Bioscience (NASDAQ), which manufactures synthetic DNA; and on the board and nominating and corporate governance committee of GCT Semiconductors (NYSE), a fabless designer and supplier of advanced 4G LTE, IoT and 5G semiconductor solutions. Mr. Chan also currently serves on the Boards of Directors of several private companies.Previoly, Mr. Chan was Chair of the board of directors, chair of the compensation committee, member of the audit committee and member of the nominating and corporate governance committee of Adesto Technologies (NASDAQ), from 2010 to June 2020, prior to its acquisition by Dialog Semiconductor plc. He also served on the board, as chair of the compensation committee, and on the nominating and corporate governance committee of Socket Mobile (NASDAQ), from 2016 to 2019. From 2007 to 2010, he was a member of the board of directors of Silicon Laboratories, Inc.(NASDAQ), and from 2010 to 2016, he was a member of the board and compensation committee, and chair of the audit committee, of Affymetrix, prior to its acquisition by Thermo Fisher. From June 2013 through September 2016, Mr. Chan also was chair of the board of Outerwall (NASDAQ) prior to its acquisition by Apollo Global Management, a private equity firm. Mr. Chan holds a Bachelor of Science degree in Electrical and Computer Engineering from the University of California at Santa Barbara and a Master's degree in Biness Administration from Santa Clara University.
- Frank Witney
-
Frank Witney，博士，曾担任总裁，2011年7月以来首席执行官和董事。卡梅隆博士担任总裁兼首席执行官Dionex公司从2009年4月到2011年5月。2008年12月至2009年4月，卡梅隆博士担任执行副总裁兼首席商务官。此前，从2002年7月到2008年12月，卡梅隆博士担任Panomics公司的总裁兼首席执行官。卡梅隆博士Cerus公司的董事会成员。
Frank Witney,most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market-leading ion and high-performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix as Executive Vice President and Chief Commercial Officer when it acquired Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer. He previously held the role of President of Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as well as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation and Standard BioTools, Inc., as well as several privately held companies, and until 2024 was a director of Telesis Bio, Inc. (formerly known as Codex DNA). Dr. Witney is an Operating Partner at Ampersand Capital Partners. - Frank Witney，博士，曾担任总裁，2011年7月以来首席执行官和董事。卡梅隆博士担任总裁兼首席执行官Dionex公司从2009年4月到2011年5月。2008年12月至2009年4月，卡梅隆博士担任执行副总裁兼首席商务官。此前，从2002年7月到2008年12月，卡梅隆博士担任Panomics公司的总裁兼首席执行官。卡梅隆博士Cerus公司的董事会成员。
- Frank Witney,most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market-leading ion and high-performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix as Executive Vice President and Chief Commercial Officer when it acquired Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer. He previously held the role of President of Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as well as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation and Standard BioTools, Inc., as well as several privately held companies, and until 2024 was a director of Telesis Bio, Inc. (formerly known as Codex DNA). Dr. Witney is an Operating Partner at Ampersand Capital Partners.
高管简历
中英对照 | 中文 | 英文- Andrew J. Last
Andrew J. Last被任命为Bio-Rad Laboratories, Inc.执行副总裁兼首席运营官，于2019年4月22日生效。在加入Bio-RAD之前，Last博士于2017年12月至2019年4月担任数字细胞生物学公司Berkeley Lights，Inc.的首席商务官，Berkeley Lights，Inc.开发和商业化平台以加速基于细胞的产品和疗法的发现，开发和交付。从2016年到2017年，Last博士担任Intrexon Corporation的首席运营官，这是一家上市的生物技术公司。在此之前，从2010年到2016年，Last博士在Affymetrix，Inc.（一家制造DNA微阵列解决方案的公司）担任高级职务，包括最近担任执行副总裁兼首席运营官。Last博士之前的其他全球领导职务包括2004年至2010年在碧迪医疗器械有限公司的高级职位；2002年至2004年在Applied Biosystems；1999年至2002年在Incyte Genomics；1987年至1999年在Monsanto公司。Last博士目前也是Oncocyte Corporation（一家上市分子诊断公司）的董事会成员，目前担任执行副总裁兼首席运营官。
Andrew J. Last,was appointed Executive Vice President and Chief Operating Officer in April 2019. Prior to joining Bio-Rad, Dr. Last was the Chief Commercial Officer of Berkeley Lights, Inc., a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development and delivery of cell-based products and therapies, from December 2017 to April 2019. From 2016 through 2017, Dr. Last was the Chief Operating Officer of Intrexon Corporation, a publicly traded biotechnology company. Prior to that, from 2010 to 2016, Dr. Last held senior roles at Affymetrix, Inc., a company that manufactures DNA microarray solutions, including most recently the role of Executive Vice President and Chief Operating Officer. Dr. Last's other previous global leadership roles have included senior positions with Becton, Dickinson and Company from 2004 to 2010; Applied Biosystems from 2002 to 2004; Incyte Genomics from 1999 to 2002; and Monsanto Company from 1987 to 1999. Dr. Last also currently serves on the Board of Directors of OncoCyte Corporation, a publicly traded molecular diagnostics company.- Andrew J. Last被任命为Bio-Rad Laboratories, Inc.执行副总裁兼首席运营官，于2019年4月22日生效。在加入Bio-RAD之前，Last博士于2017年12月至2019年4月担任数字细胞生物学公司Berkeley Lights，Inc.的首席商务官，Berkeley Lights，Inc.开发和商业化平台以加速基于细胞的产品和疗法的发现，开发和交付。从2016年到2017年，Last博士担任Intrexon Corporation的首席运营官，这是一家上市的生物技术公司。在此之前，从2010年到2016年，Last博士在Affymetrix，Inc.（一家制造DNA微阵列解决方案的公司）担任高级职务，包括最近担任执行副总裁兼首席运营官。Last博士之前的其他全球领导职务包括2004年至2010年在碧迪医疗器械有限公司的高级职位；2002年至2004年在Applied Biosystems；1999年至2002年在Incyte Genomics；1987年至1999年在Monsanto公司。Last博士目前也是Oncocyte Corporation（一家上市分子诊断公司）的董事会成员，目前担任执行副总裁兼首席运营官。
- Andrew J. Last,was appointed Executive Vice President and Chief Operating Officer in April 2019. Prior to joining Bio-Rad, Dr. Last was the Chief Commercial Officer of Berkeley Lights, Inc., a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development and delivery of cell-based products and therapies, from December 2017 to April 2019. From 2016 through 2017, Dr. Last was the Chief Operating Officer of Intrexon Corporation, a publicly traded biotechnology company. Prior to that, from 2010 to 2016, Dr. Last held senior roles at Affymetrix, Inc., a company that manufactures DNA microarray solutions, including most recently the role of Executive Vice President and Chief Operating Officer. Dr. Last's other previous global leadership roles have included senior positions with Becton, Dickinson and Company from 2004 to 2010; Applied Biosystems from 2002 to 2004; Incyte Genomics from 1999 to 2002; and Monsanto Company from 1987 to 1999. Dr. Last also currently serves on the Board of Directors of OncoCyte Corporation, a publicly traded molecular diagnostics company.
- Andrew J. Last
Andrew J. Last，在2009年12月他加入我们，目前担任执行副总裁兼首席运营官。加入美国昂飞公司之前，他在BD生物科学细胞分析单位的领导团队工作，贝克顿迪金森公司的一个部门，从2004年到2009年，他是全球营销和战略规划部门副总裁，圣地亚哥（San diego）Pharmingen业务经理。加入贝克顿迪金森公司之前，他是阿普雷拉公司应用生物系统部门领导团队的一员，从2002年至2004年，他担任基因传递部门的副总裁和总经理。
Andrew J. Last, joined the Board of Directors during December 2015. In April 2019 Dr. Last was appointed as Executive Vice President and Chief Operating Officer of Bio-Rad Laboratories, Inc. Dr. Last previously served as Chief Commercial Officer at Berkeley Lights Inc. and as Chief Operating Officer of Intrexon Corporation. From 2010 to 2016 Dr. Last was Executive Vice President and Chief Operating Officer of Affymetrix. Before joining Affymetrix, Dr. Last served as Vice President, Global and Strategic Marketing of BD Biosciences and as General Manager of Pharmingen from 2004 to 2010. From 2002 to 2004 Dr. Last held management positions at Applied Biosystems, Inc., including as Vice President and General Manager from 2003-2004 and Vice President of Marketing 2002-2003. Earlier in his career, he served in a variety of management positions at other companies, including Incyte Genomics and Monsanto. Dr. Last holds Ph.D. and MS degrees with specialization in Agrochemical Chemicals and Bio-Aeronautics, respectively, from Cranfield University, and a BS degree in Biological Sciences from the University of Leicester in the United Kingdom.- Andrew J. Last，在2009年12月他加入我们，目前担任执行副总裁兼首席运营官。加入美国昂飞公司之前，他在BD生物科学细胞分析单位的领导团队工作，贝克顿迪金森公司的一个部门，从2004年到2009年，他是全球营销和战略规划部门副总裁，圣地亚哥（San diego）Pharmingen业务经理。加入贝克顿迪金森公司之前，他是阿普雷拉公司应用生物系统部门领导团队的一员，从2002年至2004年，他担任基因传递部门的副总裁和总经理。
- Andrew J. Last, joined the Board of Directors during December 2015. In April 2019 Dr. Last was appointed as Executive Vice President and Chief Operating Officer of Bio-Rad Laboratories, Inc. Dr. Last previously served as Chief Commercial Officer at Berkeley Lights Inc. and as Chief Operating Officer of Intrexon Corporation. From 2010 to 2016 Dr. Last was Executive Vice President and Chief Operating Officer of Affymetrix. Before joining Affymetrix, Dr. Last served as Vice President, Global and Strategic Marketing of BD Biosciences and as General Manager of Pharmingen from 2004 to 2010. From 2002 to 2004 Dr. Last held management positions at Applied Biosystems, Inc., including as Vice President and General Manager from 2003-2004 and Vice President of Marketing 2002-2003. Earlier in his career, he served in a variety of management positions at other companies, including Incyte Genomics and Monsanto. Dr. Last holds Ph.D. and MS degrees with specialization in Agrochemical Chemicals and Bio-Aeronautics, respectively, from Cranfield University, and a BS degree in Biological Sciences from the University of Leicester in the United Kingdom.
- Frank Witney
Frank Witney，博士，曾担任总裁，2011年7月以来首席执行官和董事。卡梅隆博士担任总裁兼首席执行官Dionex公司从2009年4月到2011年5月。2008年12月至2009年4月，卡梅隆博士担任执行副总裁兼首席商务官。此前，从2002年7月到2008年12月，卡梅隆博士担任Panomics公司的总裁兼首席执行官。卡梅隆博士Cerus公司的董事会成员。
Frank Witney,most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market-leading ion and high-performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix as Executive Vice President and Chief Commercial Officer when it acquired Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer. He previously held the role of President of Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as well as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation and Standard BioTools, Inc., as well as several privately held companies, and until 2024 was a director of Telesis Bio, Inc. (formerly known as Codex DNA). Dr. Witney is an Operating Partner at Ampersand Capital Partners.- Frank Witney，博士，曾担任总裁，2011年7月以来首席执行官和董事。卡梅隆博士担任总裁兼首席执行官Dionex公司从2009年4月到2011年5月。2008年12月至2009年4月，卡梅隆博士担任执行副总裁兼首席商务官。此前，从2002年7月到2008年12月，卡梅隆博士担任Panomics公司的总裁兼首席执行官。卡梅隆博士Cerus公司的董事会成员。
- Frank Witney,most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market-leading ion and high-performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix as Executive Vice President and Chief Commercial Officer when it acquired Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer. He previously held the role of President of Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as well as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation and Standard BioTools, Inc., as well as several privately held companies, and until 2024 was a director of Telesis Bio, Inc. (formerly known as Codex DNA). Dr. Witney is an Operating Partner at Ampersand Capital Partners.
- David Weber
David Weber，他于2011年12月加入我们，目前担任执行副总裁兼首席商务官。2011年12月至2013年2月，他担任全球商业运作部门的高级副总裁。从2010年6月到2010年12月，韦伯先生是各种生物技术公司顾问。从2009年7月到2010年6月，韦伯在Cyntellect公司销售部门担任副总裁。从2008年2月到2009年6月，韦伯先生在莱纳斯集团担任生命科学实践的副总裁。此前，韦伯先生担任Stratagene公司Eksigent技术的总裁兼首席执行官，Amersham生物科学通用电气医疗集团美洲地区营销和业务发展的高级副总裁。
David Weber joined us in December 2011 and currently serves as Executive Vice President and Chief Commercial Officer. Between December 2011 and February 2013 he served as our Senior Vice President, Global Commercial Operations. From June 2010 to December 2011 Mr. Weber was a consultant to various biotechnology companies. Mr. Weber was at Cyntellect Inc. as its Vice President, Sales from July 2009 to June 2010. Mr. Weber was with The Linus Group from February 2008 to June 2009 as its Vice President of the Life Sciences Practice. Previously, Mr. Weber served as President and CEO of Eksigent Technologies, Senior Vice President of Marketing and Business Development of Stratagene Corp., and President, Americas Region, for Amersham Biosciences GE Healthcare.- David Weber，他于2011年12月加入我们，目前担任执行副总裁兼首席商务官。2011年12月至2013年2月，他担任全球商业运作部门的高级副总裁。从2010年6月到2010年12月，韦伯先生是各种生物技术公司顾问。从2009年7月到2010年6月，韦伯在Cyntellect公司销售部门担任副总裁。从2008年2月到2009年6月，韦伯先生在莱纳斯集团担任生命科学实践的副总裁。此前，韦伯先生担任Stratagene公司Eksigent技术的总裁兼首席执行官，Amersham生物科学通用电气医疗集团美洲地区营销和业务发展的高级副总裁。
- David Weber joined us in December 2011 and currently serves as Executive Vice President and Chief Commercial Officer. Between December 2011 and February 2013 he served as our Senior Vice President, Global Commercial Operations. From June 2010 to December 2011 Mr. Weber was a consultant to various biotechnology companies. Mr. Weber was at Cyntellect Inc. as its Vice President, Sales from July 2009 to June 2010. Mr. Weber was with The Linus Group from February 2008 to June 2009 as its Vice President of the Life Sciences Practice. Previously, Mr. Weber served as President and CEO of Eksigent Technologies, Senior Vice President of Marketing and Business Development of Stratagene Corp., and President, Americas Region, for Amersham Biosciences GE Healthcare.
- Gavin Wood
Gavin Wood，他在2006年加入我们，目前担任执行副总裁兼首席财务官。他在美国昂飞公司担任了一系列的金融岗位，包括财政副总裁、国际总监，负责欧洲和亚太地区。加入美国昂飞公司之前，伍德先生在Unipart集团公司担任一些职位，包括业务总监。伍德先生是一个特许的注册会计师，在1997年，他获得了摩根布朗斯博弗斯的伦敦会计师职位，在Grant Thornton有限责任合伙继续着自己的职业生涯之前。
Gavin Wood joined us in 2006 and currently serves as Executive Vice President and Chief Financial Officer. Mr. Wood has held a number of financial roles at the Company, including Vice President, Finance and International Controller, responsible for Europe and Asia Pacific. Prior to joining the Company, Mr. Wood held a number of positions at the Unipart Group of Companies, including Business Unit Controller. Mr. Wood is a Chartered Accountant who qualified with the London Accountancy Practice of Morgan Brown Spofforth in 1997 before continuing his career with Grant Thornton LLP.- Gavin Wood，他在2006年加入我们，目前担任执行副总裁兼首席财务官。他在美国昂飞公司担任了一系列的金融岗位，包括财政副总裁、国际总监，负责欧洲和亚太地区。加入美国昂飞公司之前，伍德先生在Unipart集团公司担任一些职位，包括业务总监。伍德先生是一个特许的注册会计师，在1997年，他获得了摩根布朗斯博弗斯的伦敦会计师职位，在Grant Thornton有限责任合伙继续着自己的职业生涯之前。
- Gavin Wood joined us in 2006 and currently serves as Executive Vice President and Chief Financial Officer. Mr. Wood has held a number of financial roles at the Company, including Vice President, Finance and International Controller, responsible for Europe and Asia Pacific. Prior to joining the Company, Mr. Wood held a number of positions at the Unipart Group of Companies, including Business Unit Controller. Mr. Wood is a Chartered Accountant who qualified with the London Accountancy Practice of Morgan Brown Spofforth in 1997 before continuing his career with Grant Thornton LLP.